Repare Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPTX research report →
Companywww.reparerx.com
Repare Therapeutics Inc. , a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
- CEO
- Steve Forte
- IPO
- 2020
- Employees
- 129
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $114.24M
- P/E
- -1.58
- P/S
- 9.62
- P/B
- 0.99
- EV/EBITDA
- -0.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 22.98%
- Op Margin
- -632.62%
- Net Margin
- -608.26%
- ROE
- -57.56%
- ROIC
- -65.03%
Growth & Income
- Revenue
- $53.48M · 4.58%
- Net Income
- $-84,689,000 · 9.71%
- EPS
- $-2.00 · 10.31%
- Op Income
- $-93,523,000
- FCF YoY
- 40.78%
Performance & Tape
- 52W High
- $2.66
- 52W Low
- $0.89
- 50D MA
- $2.35
- 200D MA
- $1.75
- Beta
- 0.96
- Avg Volume
- 1.18M
Get TickerSpark's AI analysis on RPTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | BVF PARTNERS L P/IL | other | 548,938 |
| Jan 28, 26 | SCHAFER CAROL | sell | 37,941 |
| Jan 28, 26 | SCHAFER CAROL | sell | 8,000 |
| Jan 28, 26 | RHOADS ANN D | sell | 4,000 |
| Jan 28, 26 | Civik Thomas | sell | 7,500 |
| Jan 28, 26 | Forte Steve | sell | 325,800 |
| Jan 28, 26 | Forte Steve | sell | 85,000 |
| Jan 28, 26 | Forte Steve | sell | 56,786 |
| Jan 28, 26 | Forte Steve | sell | 500,000 |
| Jan 28, 26 | Alves Sandra Isabelle Barros | sell | 26,000 |
Our RPTX Coverage
We haven't published any research on RPTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RPTX Report →